Tau Pathobiology and Excitotoxicity in Neurodegeneration and Epilepsy
Special Issue Editor
Special Issue Information
Dear Colleagues,
Tau pathology and associated excitotoxicity are increasingly recognized as key contributors to several neurological conditions, including dementia, epilepsy, and stroke. Encouragingly, tau-targeting therapies have demonstrated promising results in disease models across these disorders.
Among these, epilepsy and dementia share a particularly strong bidirectional relationship. Seizures are a common and significant complication in Alzheimer’s disease—the most prevalent form of dementia. Conversely, individuals with epilepsy are at an elevated risk of developing dementia, especially when seizures are poorly controlled.
Given these interconnections, it is essential to deepen our understanding of the tau-related mechanisms driving these conditions—both the shared pathways and those unique to each disorder. By integrating insights from research across these diseases, we can accelerate the development of more effective treatments, which are urgently needed.
This Special Issue will investigate the role of tau and its involvement in excitotoxic signalling across neurological disorders. Topics will include:
- Novel insights that shed light on the role of tau and associated signalling pathways in neuronal hyperactivity.
- Methods and models for studying tau’s contribution to neuronal hyperactivity
- Preclinical research and therapeutic strategies focused on the development of tau-targeting treatments.
- Clinical findings that shed light on tau-driven neuronal hyperactivity in neurological conditions.
- Comparative insights into the role of tau across different neurological disorders.
Dr. Janet Van Eersel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tau
- excitotoxicity
- dementia
- epilepsy
- seizures
- hyperexcitation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
